VolitionRx Limited (NYSEAMERICAN:VNRX) Short Interest Down 13.1% in March

VolitionRx Limited (NYSEAMERICAN:VNRX) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 507,400 shares, a decline of 13.1% from the February 28th total of 583,700 shares. Based on an average daily volume of 123,100 shares, the days-to-cover ratio is currently 4.1 days. Approximately 0.9% of the shares of the stock are sold short.

VolitionRx Stock Performance

VolitionRx stock traded up $0.01 during mid-day trading on Thursday, hitting $0.55. The stock had a trading volume of 21,751 shares, compared to its average volume of 115,186. VolitionRx has a one year low of $0.43 and a one year high of $1.02. The company has a market capitalization of $34.84 million, a P/E ratio of -0.98 and a beta of 1.59.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.